Fimasartan
- Generic Name
- Fimasartan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31N7OS
- CAS Number
- 247257-48-3
- Unique Ingredient Identifier
- P58222188P
- Background
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.
- Indication
Used for the treatment of hypertension and heart failure .
- Associated Conditions
- Hypertension, Essential Hypertension
- Associated Therapies
- -
A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT01878201
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT01736488
- Locations
- 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷Hallym University Medical Center, Anyang, Korea, Republic of
🇰🇷Kangnam Severance Hospital, Seoul, Korea, Republic of
A Trial of Fimasartan for Early Diastolic Heart Failure
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT01691118
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 293
- Registration Number
- NCT01672476
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects
- First Posted Date
- 2012-08-23
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT01671020
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01589380
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Korea University Anam Hospital, Seoul, Korea, Republic of
Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Seung-Jung Park
- Target Recruit Count
- 186
- Registration Number
- NCT01384747
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
- Conditions
- Essential Hypertension
- Interventions
- Drug: Fimasartan/HCTZ combinationDrug: Fimasartan
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 263
- Registration Number
- NCT01258673
- Locations
- 🇰🇷
Seoul National University Hospital, Bundang, Sungnam, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-01-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT01148368
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT01146938
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.